Low Dose Ketamine (LDK) Versus Morphine for Acute Pain Control in the Emergency Department

The purpose of this study is to compare the safety and effectiveness of intravenous low dose ketamine (LDK) to the industry standard of morphine (MOR) in regards to controlling acute pain in the emergency department.

Both LDK and morphine have side effects. The amount and character of these side effects will be compared. Additionally, the degree of sedation or agitation will be specifically measured. The aim of this current study is to make this comparison and shift the evidence for LDK use from the anecdotal to the scientific.

Study Overview

• Status: Completed
• Conditions: Back Pain; Musculoskeletal Pain; Abdomen, Acute; Other Acute Pain; Flank Pain
• Intervention / Treatment: Drug: Ketamine; Drug: Morphine

Detailed Description

Phase 1 is a randomized, controlled, double-blinded study comparing the use of low-dose ketamine (LDK) to morphine for acute pain control in emergency department patients. A convenience sample of subjects will be enrolled from a population of patients aged 18-50 who present to the Brooke Army Medical Center Emergency Department with acute abdominal pain, flank/lumbar back pain and/or pain to the extremities. To take part in the study, a need for opioid analgesia must be indicated by the treating physician in addition to the patient meeting all other study criteria.

The patient will then be randomized into one of the two treatment arms. Prior to receiving either the study medication (ketamine) or the active control (morphine) the patient will be asked to rate their pain on a numeric rating scale (NRS) with 0 being no pain and 10 being the worst pain possible. Their baseline vital signs (blood pressure, heart rate, respiratory rate and oxygen saturation) will also be documented. These vital signs and the NRS will be reassessed at 5, 10 and 20 minutes post medication dosage. At 20 minutes they will also document a Richmond Agitation Sedation Scale (RASS) score and will ask the patient if they require additional pain medication. If the patient denies the need for a second dose of medication they will continue to be re-assessed every 20 minutes (vital signs, NRS, and RASS) until either inpatient admission, discharge home, transfer to the operating room or until a total of 120 minutes after initial dosing.

If at any time during the study the patient requires a second dose of pain medication, following the administration of the med, they will be assessed for vital signs at 5,10 and 20 minutes after the dose. At 20 minutes, a RASS score and NRS score will also be documented. They will then be re-assessed every 20 minutes (vital signs, NRS, and RASS) until either inpatient admission, discharge home, transfer to the operating room or until a total of 120 minutes after initial dosing.

If they require a third dose of pain medication at any time during the study, this is considered a treatment failure and the treating physician will be contacted to provide any further pain control.

The second phase of the study will be observational. An anonymous satisfaction survey will be provided to the treating nurse, physician or physicians assistant (PA) of the patients recruited from part one of the study. The purpose of conducting the survey is so that an observation point of view can be added to the data to provide a measure of how well the patient's pain was controlled.

• Study Type: Interventional
• Enrollment (Actual): 45
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Texas
    • San Antonio, Texas, United States, 78234
      • Brooke Army Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients age 18-59 who present to the Brooke Army Medical Center Emergency Department with acute (less than 10 days) abdominal pain, flank/lumbar back pain and or/pain to the extremities, and of sufficient severity in the judgement of the ED treating physician or PA to warrant use of intravenous opioids

Exclusion Criteria:

• Poor vital sign stability hypoxia: Sats<95% hypotension: SBP<90 hypertension: SBP>180 heart rate: <50 or >120 respiratory rate: <10 or >30
• Altered mental status or intoxication
• Patient is unwilling to participate or provide informed consent
• History of chronic pain or pain syndrome with concurrent opioid medication use
• fibromyalgia
• Patient has received opioids and/or tramadol in the past 4 hours
• Prescription pain medication use (to exclude muscle relaxants, acetaminophen or NSAIDs including toradol) in the past 4 hours
• Allergy to morphine or ketamine
• Sole provider status
• Adverse reaction to morphine or ketamine in the past
• Patients, who in the opinion of the triage nurse, require immediate analgesic relief
• Patient is female of child-bearing age and unable to provide urine or serum for HCG analysis in triage
• Pregnancy or breast feeding
• Presence of oxygen dependent pulmonary disease, liver cirrhosis or Renal disease requiring dialysis. (as assessed by electronic chart review)
• Presence of Ischemic heart disease, heart failure or unstable dysrhythmias (as assessed by electronic chart review)
• Presence of intracranial mass or vascular lesion.
• Presence of psychosis or hallucinations
• Weight greater than 115kg or less than 45 kg
• History of acute ocular/head trauma
• History of increased intracranial pressure/hypertensive hydrocephalus
• Non-English speaking patients

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ketamine; 0.3 MG/KG IV KETAMINE ADMINISTERED OVER 5 MINUTES. MAX DOSE OF 25MG.	Drug: Ketamine; 0.3 mg/kg ketamine Intravenous push (IVP) over 5 minutes. Total of two possible doses.; Other Names: Ketalar
Active Comparator: Morphine; 0.1 MG/KG IV MORPHINE ADMINSITERED OVER 5 MINUTES. MAX DOSE 8MG.	Drug: Morphine; 0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.; Other Names: Kadian; MS Contin; Roxanol; Avinza

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Maximal Change in Numerical Rating Scale (NRS) Pain Score From Baseline NRS Pain Score	Numerical Rating Scale (NRS) pain score is an 11-point rating scale for pain. With 0 being no pain and 10 being the worst pain imaginable.	5,10,20,40,60,80,100,120 minutes post dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to Change in NRS Pain Score	Following dosage with study medication, the amount of time taken to demonstrate a change in the patient's NRS pain score. Time to Change in NRS Pain Score for the Reporting Group as a whole will be made	5,10, 20,40,60,80,100,120 minutes
Time to Maximal Change in NRS Pain Score	Following dosage with study medication, the interval time taken to demonstrate the maximal change in the patient's NRS pain score will be reported for each group.	5, 10, 20 minutes and then every 20 minutes to a total of 120 minutes
Incidence of Treatment Failure	Requiring more than two doses of the study medication provided for adequate pain control	120 minutes
Incidence of Side Effects, Including Outlying Vital Signs	The patient will be assessed for vital signs (blood pressure, heart rate, respiratory rate, oxygen saturation), and all side effects at 5,10,20 minutes following medication administration and then every 20 minutes until a total of 120 minutes from the first dose of study medication. All side effects and outlying vital signs will be documented.	5,10,20,40,60,80,100,120 minutes
Maximum Deviation From 0 on the Richmond Agitation Sedation Scale (RASS)	Using 0 as the "normal/baseline" on the RASS, maximal deviation in either direction will be used to demonstrate the effect of the study medications on levels of sedation or agitation. Results will be reported as Richmond Agitation Sedation Scale (RASS) scores range from: 4 Combative: Overtly combative, violent, immediate danger to staff; 3 Very agitated: Pulls or removes tube(s) or catheter(s); aggressive; 2 Agitated: Frequent non-purposeful movement; 1 Restless: Anxious but movements not aggressive. vigorous 0 Alert and calm1 Drowsy: Not fully alert, but has sustained awakening (eye-opening/eye contact) to voice (>10 seconds)2 Light sedation: Briefly awakens with eye contact to voice (<10 seconds)3 Moderate sedation: Movement or eye opening to voice (but no eye contact)4 Deep sedation: No response to voice, but movement or eye opening to physical stimulation5 Unarousable: No response to voice or physical stimulation	5,10,20,40,60,80,100,120 minutes

Collaborators and Investigators

• Sponsor: Brooke Army Medical Center
• Collaborators: U.S. Air Force Office of the Surgeon General
• Investigators: Principal Investigator: Joshua P Miller, MD, United States Air Force

Study record dates

Study Major Dates

• Study Start: February 1, 2012
• Primary Completion (Actual): March 1, 2013
• Study Completion (Actual): June 1, 2013

Study Registration Dates

• First Submitted: February 21, 2012
• First Submitted That Met QC Criteria: February 21, 2012
• First Posted (Estimate): February 24, 2012

Study Record Updates

• Last Update Posted (Actual): February 4, 2021
• Last Update Submitted That Met QC Criteria: February 3, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Keywords: Pain; Ketamine; Emergency Department; Morphine
• Additional Relevant MeSH Terms: Pathologic Processes; Pain; Neurologic Manifestations; Disease Attributes; Signs and Symptoms, Digestive; Musculoskeletal Diseases; Muscular Diseases; Abdominal Pain; Emergencies; Acute Pain; Musculoskeletal Pain; Abdomen, Acute; Flank Pain; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anesthetics, Dissociative; Anesthetics, Intravenous; Anesthetics, General; Anesthetics; Excitatory Amino Acid Antagonists; Excitatory Amino Acid Agents; Analgesics, Opioid; Narcotics; Ketamine; Morphine
• Other Study ID Numbers: C.2011.173